Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 399

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 399
---
leaf, Matthew Pauls, Todd Davis and Richard Baxter, and one member selected by Nomis Bay, namely Ezra Friedberg. The following table lists the names and ages, as of May 2, 2025, and positions of the individuals who are expected to serve as executive officers and directors of the combined company upon completion of the Merger.

| Name                   |     | Age |     | Position                                        |
| Executive Officers     |     |     |     |                                                 |
| Scott Plesha           |     |  61 |     | Chief Executive Officer, President and Director |
| Francis Knuettel II    |     |  59 |     | Chief Financial Officer                         |
| Non-employee Directors |     |     |     |                                                 |
| Todd Davis(2)          |     |  64 |     | Chairman of the Board                           |
| Richard Baxter(1)(3)   |     |  62 |     | Director                                        |
| Ezra Friedberg(1)      |     |  55 |     | Director                                        |
| Peter Greenleaf        |     |  55 |     | Director                                        |
| Dr. Richard Malamut(2) |     |  65 |     | Director                                        |
| Matthew Pauls(1)(3)    |     |  54 |     | Director                                        |

| (1) | Member of the audit committee. |

| (2) | Member of the compensation committee. |

| (3) | Member of the nominating and corporate governance committee. |

Executive Officers Scott M. Plesha has served as LNHC’s Chief Executive Officer since November 2023. Prior to joining LNHC, Mr. Plesha served as the President and Chief Commercial Officer at BioDelivery Sciences (BDSI), a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, from January 2018 until it was acquired by Collegium Pharmaceutical in 2022. Mr. Plesha joined BioDelivery Sciences in August 2015 as Senior Vice President, Sales, and assumed the additional responsibility of leading the marketing department in December 2015. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility at Solvay Pharmaceuticals. Mr. Plesha received a Bachelor of Arts in Pre-Med